soul trial oral semaglutide cardiovascular outcomes nejm 2025 results New in the May 29, 2025, issue of NEJM: Sotatercept in Pulmonary Arterial Hypertension (ZENITH phase 3 trial) https://nej.md/4iYkLbj and (SOUL trial) https://nej.md/4hHII5M Upadacitinib for Giant-Cell Arteritis 🔴Cardiovascular outcomes with semaglutide by

The future of GLP-1 therapy lies in this thoughtful integration of precise dosing strategies with comprehensive wellness approaches, always under careful medical guidance

This medication is typically prescribed following a treatment care plan that includes diet and exercise to ensure health conditions are safely and properly managed

Together, these findings position GSH not only as a guardian of cellular integrity but also as a context-dependent determinant of cell death susceptibility and therapeutic vulnerability

Boosts Mood Green coffee bean could help improve your mood

O = Reduction in composite CV events (MACE) and their individual components

Fluorescence intensity of DCF staining was analyzed on FL-1 (525 nm) using BD Accuri C6 software (BD Biosciences, San Jose, CA, USA)